Outlook Therapeutics, Inc. OTLKW 深 滬
等待開盤 09-24 09:30:00 美东时间
0.03
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.03
- 總市值 8.75万
- 52周最高 1.27
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.01
- 委 比 0.00%
- 總股本 291.70万
- 歷史最高 3.49
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.01
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Outlook Therapeutics Sets U.S. Price for LYTENAVA
Outlook Therapeutics ( ($OTLK) ) has provided an announcement. On September 16,...
09-19 05:20
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $10 to $10.5.
09-11 18:04
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
Outlook Therapeutics announced the availability of a pre-recorded fireside chat from the H.C. Wainwright Global Investment Conference, featuring CEO Bob Jahr and analyst Douglas Tsao discussing the company's recent developments. The chat is now available on-demand via the company's website. The Conference will be held September 14-16, 2026, in New York, with management available for one-on-one meetings. Outlook Therapeutics focuses on LYTENAVA, a...
09-11 11:00
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
Outlook Therapeutics announced CEO Bob Jahr's participation in a Virtual Investor CEO Connect segment discussing the FDA approval of LYTENAVA, the first FDA-approved ophthalmic bevacizumab for wet AMD. The company plans a U.S. launch by year-end 2026, targeting over $500 million in annual sales by 2030. LYTENAVA is already commercialized in Europe and the UK. The drug works by inhibiting VEGF, reducing vision loss. Key safety concerns include int...
09-10 13:10
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
Outlook Therapeutics' CEO Bob Jahr highlighted the company's transformative period following FDA approval of LYTENAVA™, the only FDA-approved ophthalmic bevacizumab for wet AMD in the U.S. During the Virtual Investor "Why Now" conference, Jahr discussed the transition from development to commercial stages, U.S. launch preparations, European presence, and potential to redefine retinal care standards. The webcast is available on-demand.
08-27 13:01
Outlook Therapeutics Announces $55 Million Equity Offering
The latest update is out from Outlook Therapeutics ( ($OTLK) ). On August 12, 2...
08-14 21:20
Outlook Therapeutics Q3 Adj. EPS $(0.09), Inline, Sales $9.000K Miss $5.300M Estimate
Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 79.55 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $9.000 thousand which missed the analy...
08-14 19:59
Outlook Therapeutics Q3 2026 Earnings Preview
Outlook Therapeutics (OTLK) is scheduled to announce Q3 earnings results on Friday, August 14th, before market open. The consensus EPS Estimate is -$0.07 (+84.1% Y/Y) and the consensus Revenue Estimat...
08-14 02:43
Outlook Therapeutics slides after pricing $55M securities offering
Outlook Therapeutics (OTLK) shares fell nearly 15% in premarket trading Thursday after the company priced a public offering of 55.6M shares and warrants for gross proceeds of about $55M. The combined ...
08-13 16:17
Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks
The latest update is out from Outlook Therapeutics ( ($OTLK) ). On July 24, 202...
08-13 04:37
